Next Article in Journal
Multifunctional Cement Composites Strain and Damage Sensors Applied on Reinforced Concrete (RC) Structural Elements
Next Article in Special Issue
The Development of Novel Near-Infrared (NIR) Tetraarylazadipyrromethene Fluorescent Dyes
Previous Article in Journal
Characterization and Stability of Tanshinone IIA Solid Dispersions with Hydroxyapatite
Previous Article in Special Issue
Solubilization of Hydrophobic Dyes in Surfactant Solutions
Materials 2013, 6(3), 817-840; doi:10.3390/ma6030817

Dye Sensitizers for Photodynamic Therapy

*  and
Fiber and Polymer Science Program, North Carolina State University, Raleigh, NC 27695-8301, USA
* Author to whom correspondence should be addressed.
Received: 31 January 2013 / Revised: 20 February 2013 / Accepted: 22 February 2013 / Published: 6 March 2013
(This article belongs to the Special Issue Advances in Colorants)
Download PDF [304 KB, uploaded 6 March 2013]


Photofrin® was first approved in the 1990s as a sensitizer for use in treating cancer via photodynamic therapy (PDT). Since then a wide variety of dye sensitizers have been developed and a few have been approved for PDT treatment of skin and organ cancers and skin diseases such as acne vulgaris. Porphyrinoid derivatives and precursors have been the most successful in producing requisite singlet oxygen, with Photofrin® still remaining the most efficient sensitizer (quantum yield = 0.89) and having broad food and drug administration (FDA) approval for treatment of multiple cancer types. Other porphyrinoid compounds that have received approval from US FDA and regulatory authorities in other countries include benzoporphyrin derivative monoacid ring A (BPD-MA), meta-tetra(hydroxyphenyl)chlorin (m-THPC), N-aspartyl chlorin e6 (NPe6), and precursors to endogenous protoporphyrin IX (PpIX): 1,5-aminolevulinic acid (ALA), methyl aminolevulinate (MAL), hexaminolevulinate (HAL). Although no non-porphyrin sensitizer has been approved for PDT applications, a small number of anthraquinone, phenothiazine, xanthene, cyanine, and curcuminoid sensitizers are under consideration and some are being evaluated in clinical trials. This review focuses on the nature of PDT, dye sensitizers that have been approved for use in PDT, and compounds that have entered or completed clinical trials as PDT sensitizers.
Keywords: photodynamic therapy; photosensitizers; porphyrins; clinical trials; target organs photodynamic therapy; photosensitizers; porphyrins; clinical trials; target organs
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Ormond, A.B.; Freeman, H.S. Dye Sensitizers for Photodynamic Therapy. Materials 2013, 6, 817-840.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Materials EISSN 1996-1944 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert